The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

The present invention relates to novel pharmaceutical compositions comprising Ledipasvir and Sofosbuvir as well as to methods for their preparation.

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: ##STR00001##
and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

A tablet press comprises a gate and a control apparatus configured to generate a switching signal. A drive apparatus is configured to move the gate in response to the switching signal received from the control apparatus between a first switching position and at least a second switching position. At least one sensor is configured to generate a detection signal when the gate reaches one of the switching positions. The control apparatus receives the detection signal and is configured to output a switching signal to the drive apparatus to at least partially move the gate back into a home position when there is a switching signal to move the gate out of the home position and there is no detection signal received from the at least one sensor. The control apparatus subsequently outputs a switching signal to again move the gate out of the home position to a target position.

A tablet press comprises a gate and a control apparatus configured to generate a switching signal. A drive apparatus is configured to move the gate in response to the switching signal received from the control apparatus between a first switching position and at least a second switching position. At least one sensor is configured to generate a detection signal when the gate reaches one of the switching positions. The control apparatus receives the detection signal and is configured to output a switching signal to the drive apparatus to at least partially move the gate back into a home position when there is a switching signal to move the gate out of the home position and there is no detection signal received from the at least one sensor. The control apparatus subsequently outputs a switching signal to again move the gate out of the home position to a target position.

The present invention relates to methods for treating uremic pruritus with anti-pruritic compositions, wherein the method provides a therapeutic effect in a patient.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.